133 results
424B3
KZIA
Kazia Therapeutics Limited
4 Jun 24
Prospectus supplement
4:06pm
of American Depositary Shares
Selling Shareholder
Material Tax Considerations
Plan of Distribution
Expenses
Legal Matters
Experts
Where You Can Find Additional … .
MATERIAL TAX CONSIDERATIONS
U.S. Taxation
This section describes certain material U.S. federal income tax consequences to a U.S. holder (as defined
F-1
KZIA
Kazia Therapeutics Limited
29 May 24
Registration statement (foreign)
8:55am
Material Tax Considerations
Plan of Distribution
Expenses
Legal Matters
Experts
Where You Can Find Additional Information
Incorporation of Documents … ”), or an independent broker-dealer, or an affiliate or associated person of a FINRA member or independent broker-dealer.
MATERIAL TAX CONSIDERATIONS
U.S. Taxation
424B3
KZIA
Kazia Therapeutics Limited
17 May 24
Prospectus supplement
4:07pm
. Issuance of Warrant ADSs shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect … by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto
6-K
EX-4.1
KZIA
Kazia Therapeutics Limited
17 May 24
Current report (foreign)
4:05pm
of the ADS.
vii. Charges, Taxes and Expenses. Issuance of Warrant ADSs shall be made without charge to the Holder for any issue or transfer tax … it for any transfer tax incidental thereto. The Company shall pay all Depositary fees for the issuance of the Warrant ADSs and all fees
6-K
EX-10.1
KZIA
Kazia Therapeutics Limited
17 May 24
Current report (foreign)
4:05pm
shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant ADSs … may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all
424B3
cyzggmd01
19 Apr 24
Prospectus supplement
4:30pm
6-K
EX-4.1
pylz9dzzbi4thic 6qm
19 Apr 24
Current report (foreign)
4:26pm
6-K
EX-10.1
cvq7sl
19 Apr 24
Current report (foreign)
4:26pm
424B3
8jb44hj iupx8
27 Mar 24
Prospectus supplement
8:37am
6-K
EX-99.1
cbhzbx v3
27 Mar 24
Current report (foreign)
8:26am
424B3
xij9g
5 Feb 24
Prospectus supplement
4:19pm
F-1
eewsn78pgey26gcnv
31 Jan 24
Registration statement (foreign)
12:00am
F-1
EX-3.1
9zogzoau rte
31 Jan 24
Registration statement (foreign)
12:00am
6-K
EX-4.1
j7b1tlbd
6 Dec 23
Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering
8:31am
6-K
EX-4.3
m20q7
6 Dec 23
Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering
8:31am
6-K
EX-10.1
yko3af7zvnggzkf60bq
6 Dec 23
Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering
8:31am
6-K
EX-4.2
5beblnjgwcrl
6 Dec 23
Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering
8:31am
424B5
pezqf14yz
4 Dec 23
Prospectus supplement for primary offering
4:05pm